Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma Plc LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.40 -5.19% 7.30 7.50 7.70 7.85 7.35 7.75 1,991,228 16:35:17
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.2 -3.2 -1.8 - 20

Evgen Pharma Share Discussion Threads

Showing 7776 to 7799 of 8975 messages
Chat Pages: Latest  323  322  321  320  319  318  317  316  315  314  313  312  Older
DateSubjectAuthorDiscuss
11/3/2021
13:12
Nico turning up on this BB is the biggest negative that I see also!
brasso3
11/3/2021
13:07
I can find one negative moneymunch - nico says he has 2 million shares in Evgen, that he is considering selling. Or has he changed his mind? :-)
clocktower
11/3/2021
13:03
It's hard to find many negatives with so much cash in the bank with so many shots on multiple targets, the oversubscribed £11m fund raise speaks volumes imho, and suggests that the new high quality sharholders such as Octopus must be highly confident of Evgen's prospects and potential going forward, and more disclosures to come in the coming days. Evgen now has c£13m cash which is a subtantial amount commensurate to their current value, and allows Huw and the team to accelerate development of the pipeline and grow the company for the next couple of years, which offers a very exciting risk/reward opportunity and tremendous upside potential on success, for all invested. Gla ;-)
moneymunch
11/3/2021
12:24
It is what it is I was on the zoom so I heard first hand how much money they were looking to raise
nico115
11/3/2021
11:45
Yes, first hurdle clear and as you say Bumpa, nothing unexpected, so no surprises to see little movement in the share price today. Was nervous before I opened the RNS though. Nice to have a clear indication of when we will get the news that will either light the touch paper, or cause discomfort, from the reviewed data of this trial. Hopefully we will enjoy a nice rise as we approach that period. While I would have also liked to see RG increase his position here, I remember him dumping stock in other shares that went on to rocket shortly afterwards, so while he is clearly an impressive investor, he does not always get it right! I certainly hope he is wrong here :) A part of me also hopes he is wrong with his increased holding of C4X, which I mentioned being tied up here at the time meant I did not have the cash available to invest there, when the share price was something like 16p. Laugh and the whole world laughs with you - apparently! GLA.
lovewinshatelosses
11/3/2021
11:04
There's no need for recollections here, we have RNSs. Unless nico reckons he heard Huw talking about raising £3m (or was it £5m like he said in his first post) down the pub?
on target
11/3/2021
10:42
As the Queen has suggest about Meghan's comments - On Target - Different recollections
clocktower
11/3/2021
10:16
Says it like it is, apart from making up stuff about the placing.
on target
11/3/2021
10:10
Say it like it is nico115. Nice positive sounds from you today - "Limited downside now" If that's not a buy signal from you, what is. :-)
clocktower
11/3/2021
08:13
good news on safety, though not unexpected. The next one is the big one.
bumpa33
11/3/2021
07:43
Positive interim efficacy data on SFX-01 for Covid/Ards from Prof Chalmers will be a complete game changer, undoubted transformational upside potential on multiple fronts and fully funded for the forseeable......a very attractive risk/reward opportunity from this current rock bottom low. Gla ;-)
moneymunch
11/3/2021
07:41
After my earlier pessimism, I received 70% of my excess (27913/40000), which is more than I expected.
ewanwhose
11/3/2021
07:34
Good rns today Limited downside now Let's agree to disagree about director buys as free bet for them which is wrong
nico115
11/3/2021
07:20
Prof Chalmers, Lead investigator for SFX-01 Covid/ARDS patient trials, is on the organisation committee for the following event, and so every chance that he could be reporting good news on SFX-01's efficacy for Covid/Ards 29th April 2021.Gla ;-) COVID-19: State of the art – DRAGON IMI project 29 April, 2021 Online A full-day virtual event dedicated to COVID-19, where top level faculty will share the latest advances, data and best practices relating to SARS-CoV-2 and COVID-19. “This event brings together world-leaders tackling COVD-19 and how different digital approaches to big data will help us to defeat the pandemic” – Professor Christopher Brightling, event co-chair. htTps://www.ersnet.org/events/covid-19-state-of-the-art-dragon-imi-project/?preview_id=129976
moneymunch
11/3/2021
07:18
We might not be going to the moon just yet....but we're certainly preparing the rocket!
hodhasharon
11/3/2021
07:13
Lol....yep, of course it is.....even better, i was mixing up my H & Q's...;-)
moneymunch
11/3/2021
07:12
Q2 is April to end June
2seabass
11/3/2021
07:08
Just seen that thanks!
awise355
11/3/2021
07:07
Yep, but the all important interim efficacy data will be available during Q2 2021, ie any time from July. Gl ;-)
moneymunch
11/3/2021
07:04
Exciting times!!! Gla HOLDERS!!!! ;-)))
moneymunch
11/3/2021
07:03
End of 2021? Expected I missed that
awise355
11/3/2021
07:03
RNS Number : 8634R Evgen Pharma PLC 11 March 2021 Evgen Pharma plc ("Evgen" or the "Company") Update on Data Safety Review for STAR COVID-19 trial Review of Patient Safety and Data Quality confirms no concerns with trial Evgen Pharma plc (AIM: EVG), a clinical stage drug development company, announces that after a review of the first 60 patients enrolled, the Data Safety Monitoring Committee ("DMC") for the STAR COVID-19 ("SFX-01 Treatment for Acute Respiratory infections") trial has concluded that there are no concerns regarding patient safety or data quality that would prevent continuation of the trial. The Phase II/III trial is a double blind, randomised, placebo-controlled study of the Company's lead asset, SFX-01, in patients with acute respiratory distress syndrome (''ARDS''). The trial is co-sponsored by the University of Dundee and NHS Tayside and funded by the UK charity LifeArc. It is investigating whether the Company's lead asset, SFX-01, can reduce the severity, or prevent the onset of, acute respiratory distress syndrome in patients with suspected COVID-19. Patients may be included in the study if they are infected with SARS-CoV-2 or other respiratory infections causing community-acquired pneumonia. Following this positive step, the next event in the trial involves an assessment of safety and futility by the DMC of unblinded data on the first 100 patients treated. In addition to the DMC safety and futility assessment, Dundee University has decided to review the top-level unblinded data in a preliminary assessment of possible efficacy. This may lead to adjustments to the design of the trial for remaining patients, including in-patient numbers, and possibly early termination for either safety, futility or alternatively, strong efficacy. It is expected that this initial data will be available during Q2 of the calendar year 2021. Completion of recruitment to the STAR trial is anticipated at the end of 2021/early 2022, assuming there are no substantial changes in the total patients to be recruited. Dr Huw Jones, CEO of Evgen, commented: "We are pleased with the conclusion of the data monitoring committee with regard to safety and data quality in the STAR COVID 19 study. The former conclusion reinforces what we know about the positive safety and tolerability of SFX-01 from previous studies and the latter is yet another testament to the excellent work carried out by Professor James Chalmers and his colleagues at Dundee under challenging circumstances."
moneymunch
11/3/2021
06:56
Huw bought 65k shares, yet he already had 2.9m share options.....Sue Foden bought 125k shares as well as share options in place, not every Director is cash rich as you think they are, and if i had 2.9m share options in Evgen, i personally would be investing my money elsewhere to spread the investment risk, there are no guarantees in this game but there lies the transformational upside opportunity on Evgen's prospects and potential, multiple shots on multiple targets and attracting the substantial investment from Octopus the UK's leading VC fund, and more disclosures to come. Share options in place can only be exercised after achieving significant share price value, and so a win win win for all concerned with Huw and the BoD incetivised to deliver growth and shareholder value. Gla Holders....this will move BIG time as the placing dust settles and Huw updates the market on progress made.....and fully funded until mid 2023 at 8p a share...Fill Ya Boots!!!!! ;-)
moneymunch
Chat Pages: Latest  323  322  321  320  319  318  317  316  315  314  313  312  Older
ADVFN Advertorial
Your Recent History
LSE
EVG
Evgen Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210618 03:53:35